TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The CONQUEST-Study. Evaluation of Clinical Endpoints for Treatment-induced Changes in GERD-related Symptoms (BY1023/NL511)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Outpatients of at least 18 years of age~* History of GERD-related symptoms of at least 6 months prior to baseline visit~* Endoscopically-confirmed GERD or non-erosive GERD~Exclusion Criteria:~* Zollinger-Ellison syndrome or other gastric hypersecretory condition~* Acute peptic ulcer and/or ulcer complications~* Pyloric stenosis~* Severe or unstable cardiovascular, pulmonary, and/or endocrine disease~* Pregnancy, breast feeding, intention to become pregnant during the course of the study or lack of reliable contraception in women of child-bearing potential~* Intake of any medication for the purpose of eradication of Helicobacter pylori (H. pylori) within the last 28 days prior to study start~* Intake of systemic glucocorticoids or non-steroidal anti-inflammatory drugs including cyclooxygenase-2 (COX-2) inhibitors for more than 3 consecutive days within the last 28 days prior to study start; with the exception of acetylsalicylic acid not more than 150 mg per day

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1. (Type: ACTIVE_COMPARATOR): 40 mg Pantoprazole

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have histologically or cytologically invasive breast cancer, with metastatic disease at the time of screening~* Measurable Central Nervous System (CNS) disease, as defined as at least one lesion \> or equal too 10mm in longest dimension~* New or progressive CNS lesions after at least one prior standard CNS-directed therapy for treatment of brain metastases, which could include surgical resection, whole brain radiotherapy (WBRT), and/or stereotactic radiosurgery (SRS). Patients must have received prior WBRT, SRS or both.~* Patient has been evaluated by a radiation oncologist, who feels that the plan to evaluate systemic chemotherapy in place of additional brain radiotherapy is an acceptable option~* No increase in corticosteroid use in the week prior to study entry~* Any number prior lines of chemotherapy for metastatic breast cancer~* 18 years of age of older~* Life expectancy of greater than 12 weeks~* ECOG Performance Status 0-2~* Patients must have normal organ function as outlined in the protocol~Exclusion Criteria:~* Patients who have had chemotherapy within 3 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier~* Patients who have had XRT within 3 weeks prior to entering the study or those who have not recovered from adverse events due to XRT~* Patients may not be receiving any other investigational agent~* Patients may not be receiving any cancer-directed therapy~* Prior treatment with investigational chemotherapy for brain metastases~* Prior treatment with epothilone for metastatic breast cancer~* Leptomeningeal carcinomatosis as the only site of CNS involvement.~* Concurrent treatment with an enzyme inducing antiepileptic drug, including phenytoin, carbamezepine, phenobarbital, or oxacarbazepine~* More than 2 seizures over the last four weeks prior to study entry~* Known contraindication to MRI or gadolinium contrast, such as cardiac pacemaker, ocular foreign body, or shrapnel~* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements~* Pregnant or breastfeeding women.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ZK219477 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Luteal Progesterone Support on Pregnancy Rates With Combined Clomid/ Gonadotropin & IUI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-37~* BMI 19-34 kg/m2~* Day 2-3 Follicle stimulating hormone (FSH) less than 10IU/mL~* Estradiol (E2) less than 80 pg/mL~* Anti-mullerian hormone (AMH) more than 1.5 ng/mL; or antral follicle count (AFC) up to 10~* Two patent fallopian tubes confirmed by hysterosalpingogram (HSG) or chromopertubation~* Normal uterine cavity confirmed by HSG, saline sonohysterogram (SIS) or hysteroscopy~Exclusion Criteria:~* Severe male factor (total count less than 10 million sperm)~* Systemic diseases not limited to diabetes~* Pregnancy within 3 months~* More than 1 prior cycle of gonadotropin treatment~* Any ovarian cyst \>15mm that has persisted for \> 1 month~* Endometrioma and/or Endometriosis-stage III or IV~* Submucosal uterine fibroids; untreated endometrial polyps \>1 cm;abnormal reproductive tract bleeding~* Intolerance or allergy to study drug~* Substance abuse (including alcohol and tobacco)~* History of chemotherapy (except for gestational conditions) or radiotherapy~* Minors and those adults not capable of consenting on their own

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 37 Years
- Healthy Volunteers: t

Study Arms:
- Control (Type: ACTIVE_COMPARATOR): This arm receives Menopur 150 international units x 1 dose
- Treatment (Type: ACTIVE_COMPARATOR): This arm receives Menopur 150 international units x 1 dose and Endometrin 100mg twice a day x 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Using Wearable Technology to Detect Symptoms of Posttraumatic Stress Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria for participants with PTSD: Individuals are eligible for the current study if they:~1. Are 18 years or older~2. Are fluent in English~3. Have an active smart phone or smart device with full data and Bluetooth capability~4. Have experienced a Criterion A traumatic event during their lifetime~5. Have a PTSD diagnosis verified by the Clinician Administered PTSD Scale for DSM-5 and a symptom severity score of 35 or higher.~6. Are willing and able to complete self-report measures and clinician-rated assessments at multiple time points over the course of the study~7. Are willing to wear a smart device 24/7 over the course of one month.~Exclusion Criteria for PTSD participants: Individuals are excluded from the current study if:~1. The traumatic event occurred in the past month~2. They are currently suicidal or homicidal~3. They have a history of psychosis or mania~4. They have a known, diagnosed heart condition~5. They are currently receiving treatment for their PTSD or have completed an evidence- based PTSD treatment in the past 3 months~6. They have a serious or unstable medical illness or instability for which hospitalization may be likely~7. Subjects who, at the time of consent, appear to have extenuating life circumstances (unstable housing, no internet access, etc.) which, in the judgement of the Principal Investigator, could affect their ability to participate in the study~Inclusion Criteria for healthy controls:~Individuals are eligible for the current study if they:~1. Are 18 years or older~2. Are fluent in English~3. Have an active smart phone or smart device with full data and Bluetooth capability~4. Are willing and able to complete self-report measures and clinician-rated assessments at multiple time points over the course of the study~5. Are willing to wear a smart device 24/7 over the course of one month.~Exclusion Criteria for healthy controls:~Individuals are excluded from the current study if they:~1. Score a 10 or higher on the Clinician Administered PTSD Scale for DSM-5~2. Known or diagnosed heart condition~3. Known or diagnosed psychiatric condition~4. Currently or have previously received psychiatric care in the past 3 months~5. Subjects who, at the time of consent, appear to have extenuating life circumstances (unstable housing, no internet access, etc.) which, in the judgement of the Principal Investigator, could affect their ability to participate in the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Healthy Control (Type: None): None
- PTSD (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Placebo Controlled Trial of Bosentan in Scleroderma Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* SSc patients \> 18 with NYHA functional Class I/II symptoms, informed consent, and who are willing to participate in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) long term study (Georgetown IRB 04-227)~* Right heart catheterization with~  1. Normal Mean Pulmonary Arterial Pressure (PAP) at rest~ 2. Mean PAP \> 30 with exercise~ 3. Wedge Pressure \< 18~* Entry criteria for participating in the exercise echocardiogram study (Georegtown IRB 03-363)~  1. Diffusing Capacity (DLCO) \<60 with a Forced Vital Capacity (FVC) \>60%, or~ 2. FVC/DLCO \> 1.6, or~ 3. a resting Pulmonary Arterial Systolic Pressure (PASP)\> 40mmHg~Exclusion Criteria:~* Established resting pulmonary hypertension~* Congestive heart failure~* Diastolic dysfunction~* Pregnancy~* Inability to adequately walk/exercise~* Severe liver disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bosentan (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy Plus Radiation Therapy Followed by Surgery in Treating Patients With Stage IIIB Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed primary stage IIIB non-small cell lung cancer (NSCLC)~  * T4, any N, M0 or any T, N3, M0~ * No N3 disease due to scalene or supraclavicular lymph node involvement~* No primary tumors located in the lower lobe combined with contralateral upper higher mediastinal lymph node involvement~* No mixed tumor types with small cell lung cancer~* At least 1 unidimensionally measurable target lesion~  * At least 20 mm by conventional techniques OR~ * At least 10 mm by spiral CT scan~* No pre-existing pleural or pericardial effusion~* No CNS involvement by CT scan or MRI~PATIENT CHARACTERISTICS:~Age:~* 18 to 75~Performance status:~* WHO 0-1~Life expectancy:~* Not specified~Hematopoietic:~* Absolute neutrophil count at least 2,000/mm\^3~* Platelet count at least 100,000/mm \^3~Hepatic:~* Bilirubin no greater than 1.5 times upper limit of normal (ULN)~* AST/ALT no greater than 1.5 times ULN~* Alkaline phosphatase no greater than 2.5 times ULN~Renal:~* Creatinine no greater than 1.25 times ULN~* Creatinine clearance at least 60 mL/min~Cardiovascular:~* No clinical evidence of superior vena cava syndrome~Pulmonary:~* Postoperative FEV1 and KCO greater than 40% predicted~* VO2 max greater than 15 mL/min/kg (if postoperative KCO no greater than 40% predicted)~Other:~* No other primary malignancy except carcinoma in situ of the cervix, adequately treated basal cell skin cancer, or other malignancy treated more than 5 years ago without recurrence (excluding melanoma, breast cancer, or hypernephroma)~* No active uncontrolled infection requiring IV antibiotics~* No pre-existing sensory neurotoxicity grade 2 or greater~* No psychological, familial, sociological, or geographical condition that would preclude study compliance~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No prior immunotherapy for NSCLC~* No concurrent immunotherapy during induction chemoradiotherapy~* Concurrent colony stimulating factors allowed~Chemotherapy:~* No prior chemotherapy for NSCLC~Endocrine therapy:~* No concurrent anticancer hormonal agents (except corticosteroids for antiemetic prophylaxis) during induction chemoradiotherapy~Radiotherapy:~* No prior radiotherapy for NSCLC~Surgery:~* No prior surgery for NSCLC~Other:~* No other concurrent anticancer drugs during induction chemoradiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Lubiprostone as a Treatment for Constipation in Parkinson's Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 50-85 years~2. Diagnosis of Parkinson's disease~3. Constipation as defined by the Rome III committee~4. BSFS of more or equal to 1 and less or equal to 3~5. Normal colonoscopy in the last 5 years( normal defined as absence of obstructive lesions in the colon)~6. All women subjects will be post menopausal or surgically sterile.~Exclusion Criteria:~1. Known hypersensitivity reaction to Amitiza ( Lubiprostone)~2. Known significant adverse effects to previous treatment with Lubiprostone which include; new or worsening abdominal pain, severe diarrhea, nausea, vomiting, and severe headache.~3. Renal dysfunction with creatinine clearance less than 15 ml/min~4. Abnormal liver enzymes or history of chronic liver disorder~5. History of bowel obstruction, , or abdominal adhesions .~6. Abnormal Colonoscopy ( obstructive lesions within the colon)~7. Inability to give informed consent

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Patients (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of FUSION™ Vascular Graft for Above Knee Targets

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* No known malignant disease~* Patient was willing and able to have follow-up visits and examinations~* Peripheral arterial occlusive disease (PAOD) requiring treatment of the femoral artery; Fontaine stage IIb, III and IV with dry peripheral gangrene, and suitable for surgery~* Patient was not participating in other clinical trials that would conflict with this protocol~* Patient agreed to the study provisions and provided written informed consent~Exclusion Criteria:~* Urgent or emergent surgery of any kind~* Documented acute or suspected systemic infection~* Life expectancy of less than one year~* Patients who had a minor or major stroke within 6 weeks of the procedure or who had evidence of prior massive stroke~* Patients who had experienced a myocardial infarction within 6 weeks prior to the procedure or had unstable angina pectoris~* Severe chronic renal insufficiency or undergoing hemodialysis~* Patients treated with coumadin (warfarin) that had not been stopped within 72 before enrollment~* Medical conditions requiring oral anticoagulation~* Antiplatelet therapy with clopidogrel or dual antiplatelet as well as any other antithrombotic medication within 7 days prior to scheduled bypass surgery except unfractionated heparin or aspirin~* International normalized ratio (INR) \> 2.0~* Known hypersensitivity to heparin~* Patient not tolerating aspirin~* Previous history of bypass surgery in the target limb~* Patient with category 6 ischemia (tissue loss)~* Acute limb ischemia of any grade (0-3)~* Patient with no outflow beyond the popliteal artery~* Pregnant or may become pregnant during the course of the study~* Uncontrolled arterial hypertension (BP \> 200 mmHg) at 2 successive readings~* Anaemia (hemoglobin \< 8 g/ml)~* Thrombocytopenia \< 50 g/L~* Active bleeding according to clinical judgment~* Infected wet gangrene of any size and location at the target limb~* Compromised arterial flow~* Patient unwilling or unable to comply with follow-up requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- FUSION Vascular Graft (Type: EXPERIMENTAL): All subjects who received a FUSION Vascular Graft at the baseline implant procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Magnesium Sulfate in the Prevention of Post-ERCP Pancreatitis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* medical indication for ERCP~* first ERCP in the Patient~* signed informed consent forms for ERCP and MagPEP trial~Exclusion Criteria:~* privious ERCP~* hypersensitivity to study medication or similar substances~* participation in another clinical trial during the last 4 weeks~* addictive disorders~* women who are pregnant or breastfeeding~* unwillingness or inability to comply with study protocol~* acute pancreatitis~* renal insufficiency of stage 4 or higher~* active hyperthyreosis~* symptomatic bradycardia (\<35/min)~* known history of Myasthenia gravis~* AV bock \> first degree or other bradycardic disorders of conductivity~* liver cirrhosis Child C~* coagulation disorder~* urinary stone diathesis (calcium magnesium ammonium phosphate stones)~* patients who are not able to provide informed consent~* intake of magnesium during the last 14 days~* intake of calcium antagonists

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Magnesium (Type: EXPERIMENTAL): Patients receive 2 infusions of 500 ml NaCl 0,9%: the first one 60 min before ERCP and the second one 6 hours after ERCP.~With each infusion 10 ml magnesium sulfate (4930 mg magnesium sulfate = 20 mmol magnesium) are administered (total dose: 9860 mg magnesium sulfate).
- Placebo (NaCl 0,9%) (Type: PLACEBO_COMPARATOR): Patients receive 2 infusions of 500 ml NaCl 0,9%: the first one 60 min before ERCP and the second one 6 hours after ERCP.~To each infusion 10 ml NaCl 0.9% (Placebo) will be added .

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Permeability MRI in Cerebral Cavernous Malformations Type 1 in New Mexico: Effects of Statins

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of cerebral cavernous malformations-common Hispanic mutation (CCM1-CHM)~* Must be willing to travel to the University of New Mexico in Albuquerque, NM for 5 visits over the course of three months.~Exclusion Criteria:~* Incarceration~* Unable to pass MRI safety screening (pregnant females, claustrophics, or those with certain metallic items implanted in their bodies)~* Low kidney function or transplants, an eGFR below 60 mL/min~* Currently taking statin medications or have taken statin medications in the past 6 months~* Known allergy or intolerance to statins~* Known allergy or intolerance to gadolinium~* Liver dysfunction at baseline, AST \> 47 and/or ALT \> 49~* Consumption of large quantities of alcohol, men who consume more than 2 daily drinks and women who consume more than one daily drink~* CK level of 232 or higher~* Triglycerides greater than or equal to 500.~* Medications: gemfibrozil, cyclosporine, danazol, itraconazole, ketoconazole, posaconazole, ethromycin, clarithomycin, telithromycin, HIV protease inhibitors, nefazoldone, amiodarone, verapamil, dilitiazem, amlodipine, or ranalazine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Simvastatin (Type: EXPERIMENTAL): 20-40 mg tablet taken daily by mouth. Month 1: 20 mg; Months 2 and 3: 40 mg.
- No Treatment (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy